Enfortumab (powder)
Based on 4 publication(s) in Google Scholar
Enfortumab (powder) is a humanized derived anti-Nectin-4 antibody that can be conjugated with the highly efficient microtubule disruptor MMAE (HY-15162) to generate the antibody agent conjugate (ADC) Enfortumab vedotin-ejfv (HY-P99016A). Enfortumab (powder) can be used for the study of locally advanced and metastatic urothelial carcinoma.
For research use only. We do not sell to patients.
- CAS No.: 1448664-46-7
- Molecular Weight:145.44 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Enfortumab (powder)
More
Biological Activity
Nectin-4
Enfortumab (powder) Vedotin is an antibody-drug conjugate (ADC) consisting of a monoclonal antibody targeting nectin-4 and Monomethyl auristatin E (HY-15162). Nectin-4 is highly expressed in urothelial carcinoma, and MMAE is a microtubule disruptor. Enfortumab (powder) Vedotin binds to nectin-4 and delivers MMAE to the interior of tumor cells, thereby inhibiting the formation of cell microtubules, leading to cell cycle arrest and apoptosis[1][2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1448664-46-7
-
Molecular Weight 145.44 kDa
-
SMILES
[Enfortumab (powder)]
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
J Med Chem
"Precision on Two Wheels"─Structural Refinement of 64Cu- and 68Ga-Labeled Bicyclic Peptides Targeting Nectin-4 for Improved Tumor Imaging: From Preclinical Development to First-in-Human Application. [Abstract]2025 Oct 23;68(20):21962-21987. PMID: 41081542 -
J Chromatogr A
Comprehensive evaluation of the analytical toolbox for commercial cysteine-linked antibody-drug conjugates. [Abstract]2026 Jun 21:1777:466966. PMID: 41962243 -
Mol Carcinog
Targeting TROP2 and Exploiting AUNIP as a Determinant of ADC Cytotoxicity and Chemosensitivity in HNSCC and ESCA Cancers. [Abstract]2026 May 7. PMID: 42096614 -
Purity & Documentation
References
[1]. Challita-Eid PM, et al. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Cancer Res. 2016 May 15;76(10):3003-13. [Content Brief]
[2]. O'Donnell PH, et al. Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer. J Clin Oncol. 2023 Sep 1;41(25):4107-4117. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Enfortumab (powder) Related Classifications
HY-P99016C Related Classifications
Powered by Bioz